Introduction
============

Olefin metathesis is a convenient and powerful methodology for the construction of carbon--carbon double bonds.^[@cit1]^ Due to their high activity and functional group tolerance, ruthenium-based catalysts have been utilized in a variety fields including natural product synthesis,^[@cit2]^ biochemistry,^[@cit3]^ green chemistry^[@cit4]^ and polymer chemistry.^[@cit5]^ Along with the expansion of these applications, the catalysts themselves have dramatically evolved. In particular, the introduction of an *N*-heterocyclic carbene (NHC) ligand in place of a phosphine ligand led to a large enhancement in catalyst activity and stability.^[@cit6]^ These types of catalysts are widely used in both academic and industrial laboratories.

The modification of X-type ligands, which are generally chlorides in the original catalyst systems, is becoming a popular avenue of investigation because of their easy substitution and large impact on catalyst performance. Buchmeiser *et al.* first utilized silver([i]{.smallcaps}) salts to remove a chloride ligand and simultaneously introduce an anionic ligand in its place.^[@cit7]^ They expanded this methodology to form solid supported systems where a catalyst is bound to a monolith through a polymeric X-type ligand.^[@cit7a],[@cit7b]^ Additionally, Hoveyda *et al.* formed a bidentate chiral NHC ligated complex through similar ligand exchange reactions which enabled highly enantioselective asymmetric ring-opening cross metathesis (AROM) and cross metathesis (CM).^[@cit8]^ We recently reported a family of NHC chelated catalysts which were produced by coordination of two pivalate ligands and subsequent intramolecular C--H bond activation.^[@cit9]^ This family of catalysts has showed very high activity and *Z*-selectivity in a variety of metathesis reactions.^[@cit10]^

The formation of catalysts that are cationic at the metal center or contain pendant positively charged groups has been previously reported (**1--6** in [Fig. 1](#fig1){ref-type="fig"}). One of the remarkable examples are ionic liquid tagged catalysts, like **1** and **2**,^[@cit11]^ that have an oligomeric tether capped with a cationic imidazolium group. Due to their cationic charge, they can be immobilized in an ionic liquid phase and behave as supported catalysts, achieving efficient catalyst recyclability. Several cationic catalysts, in which the ruthenium center is positively charged, have been also reported.^[@cit12]^ Among these catalysts, **3** shows much higher activity in ring-opening metathesis polymerization (ROMP) reactions of cyclooctene compared to standard NHC-ligated catalyst.^[@cit12a]^ In ring-closing metathesis (RCM) reactions of a tetra-substituted olefin, which is one of the toughest olefin metathesis transformations, **5** surpasses the second generation catalyst.^[@cit12c]^

![Examples of cationic ruthenium alkylidene catalysts.](c5dt04506a-f1){#fig1}

Relying on the recent successes mentioned above, modification of the X-type ligand to produce cationic ruthenium-based catalysts is highly promising in improving catalyst efficiency and expanding their applications. Therefore, the discovery of facile methodologies to prepare these types of catalysts is highly desired. Here we report the convenient syntheses of cationic catalysts bearing bulky phosphine ligands, and explore their reactivity in standard metathesis reactions.

Results and discussion
======================

Catalyst syntheses
------------------

We chose \[H~2~IMes~2~\]RuCl~2~\[0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 1111111111111111111111111111111111 1111111111111111111111111111111111 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000 0000000000000000000000000000000000CH-*o*-(O^i^Pr)C~6~H~4~\] (**7**, H~2~I = imidazolidinylidene, Mes = mesityl) as a starting complex due to its high activity in various metathesis reactions.^[@cit13]^ It was previously reported that AgBF~4~ is capable of extracting a single chloride ligand from complex **7**.^[@cit12d]^ When **7** was reacted with AgBF~4~ in the presence of PPh~3~, a cationic catalyst bearing a bulky PPh~3~ ligand (**8a**) was obtained in high yield. In the same manner, other silver salts of non-coordinating or weekly coordinating anions also provided similar cationic catalysts (**8b--d**) ([Scheme 1](#sch1){ref-type="fig"}). In the ^1^H NMR spectra of **8**, signals for the methyl groups of the two *N*-mesityl substituents appear as all inequivalent, suggesting that the bulky PPh~3~ ligand hinders rotation of the NHC ligand at room temperature. X-ray quality crystals of **8c** were grown and the crystal structure indicates steric repulsion between a phenyl group of the PPh~3~ ligand and the *N*-mesityl group of the NHC ligand ([Fig. 2](#fig2){ref-type="fig"}). Compared to **7**,^[@cit13]^ **8c** has smaller C1--Ru1--O1 angle (96.73(5)° *versus* 176.2(14)°) and larger C1--Ru1--Cl1 angle (154.88(4)° *versus* 96.6(12)° and 90.9(12)°). The latter structural feature is also observed in previously reported complexes **4** ^[@cit12b]^ and **5** ^[@cit12c]^ ([Fig. 1](#fig1){ref-type="fig"}).
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![X-ray crystal structure of **8c**. Displacement ellipsoids are drawn at 50% probability. For clarity, hydrogen atoms and the counter anion PF~6~ have been omitted. Selected bond length (Å) for **8c**: C1--Ru1 2.0723(15), C22--Ru1 1.8349(15), O1--Ru1 2.3442(10), Cl1--Ru1 2.3517(4), P1--Ru1 2.2788(4).](c5dt04506a-f2){#fig2}

Next, we were able to synthesize cationic diphosphine chelated catalysts derived from \[H~2~IMes~2~\]RuCl~2~(PPh~3~)(CHPh) (**9**)^[@cit14]^ ([Scheme 2](#sch2){ref-type="fig"}). First, **9** was exposed to TMS(OTf) causing the substitution of one chloride ligand with an OTf anion, yielding mono-triflate complex **10**. Next, diphosphines DPPE and DPPP were added, subsequently replacing both the labile PPh~3~ and OTf ligands, and afforded cationic diphosphine chelated complexes **11a** and **11b**, respectively. As a result of coupling with two unequivalent phosphorus atoms, the signal of the benzylidene proton appeared as doublet of doublets in the ^1^H NMR spectrum. Additionally, a large difference in the chemical shifts of the two phosphorus atoms in the ^31^P NMR spectrum suggests that the diphosphine ligand coordinates to the ruthenium center with one phosphorus atom at the equatorial position and the other one at the axial position in the catalyst.
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Metathesis assays
-----------------

### Ring closing metathesis (RCM)

First, the standard RCM reaction of diethyldiallyl malonate (**12**)^[@cit15]^ was carried out using catalysts **8a--c** and **11a--b** in order to evaluate their activities ([Scheme 3](#sch3){ref-type="fig"}). As shown in [Fig. 3](#fig3){ref-type="fig"}, mono-phosphine catalysts **8a--c** showed moderate activities and the conversion to reach ∼90% after 6 hours. The lower activity of PPh~3~-substituted complexes **8a--c** compared to **7** may be due to the steric bulkiness of the phosphine ligand that possibly hinders olefin coordination. It should be noted that no significant dependence of the counter anions on metathesis activity was observed. The anions, which potentially could coordinate to the ruthenium center and compete with olefin coordination did not affect catalyst reactivity under the presented conditions. Alternatively, diphosphine-substituted catalysts **11a--b** exhibited poor activity, providing significantly low to no conversion of **12**. Considering the mechanism of initiation, it is seemingly necessary to dissociate one phosphorous arm from the ruthenium center in order to make a vacant site for coordination of incoming olefin ([Fig. 4](#fig4){ref-type="fig"}). Because the chelated form seems like a dormant species, the high energy barrier of the dechelation of the diphosphine ligand is thought to decelerate the catalyst initiation and overall metathesis reaction.
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![Plots for conversion *vs.* time for RCM of **12**. All reactions were carried out using 0.080 mmol of **12** and 0.80 μmol of catalyst in 0.8 ml of CD~2~Cl~2~ at 30 °C. Data for **7** is from [@cit15]. ^*a*^ Conversion of **12** to **13** determined by ^1^H NMR analysis.](c5dt04506a-f3){#fig3}

![One plausible mechanism of catalyst initiation for **11a**.](c5dt04506a-f4){#fig4}

### Cross metathesis (CM)

In order to evaluate the activity and stereoselectivity of these new catalysts, the standard CM reaction of allylbenzene (**14**) and *cis*-1,4-diacetoxy-2-butene (**15**)^[@cit15]^ was carried out ([Scheme 4](#sch4){ref-type="fig"}). Selected data for the cationic catalysts are summarized in [Table 1](#tab1){ref-type="table"} and plotted in [Fig. 5](#fig5){ref-type="fig"}. Similar to the RCM assay above, while **8a--b** and **11a** showed moderate activities, no conversion was observed when **11b** was used. It has been reported that some asymmetric ruthenium-based catalysts substituted with one bulky X-type ligand tend to give lower *E*/*Z* ratio of the products compared to catalyst **7**.^[@cit16]^ In one case, a ruthenium catalyst bearing a single bulky thiolate ligand (**18**) provided an *E*/*Z* ratio of 0.20 in the homocoupling of substrate **14** ([Fig. 6](#fig6){ref-type="fig"}).^[@cit16b]^ However, the *E*/*Z* ratio of product **16** formed by the cationic catalysts reported here are very similar to the one by the dichloro analogue **7** ([Fig. 5(b)](#fig5){ref-type="fig"}). This possibly indicates that the phosphine ligands are too far from the reaction center to influence the stereoselectivity ([Fig. 6](#fig6){ref-type="fig"}).
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![Plots for (a) conversion *vs.* time and (b) *E*/*Z* ratio *vs.* conversion for CM of **14** and **15**. ^*a*^ Conversion of **14** to **16** determined by GC analysis.^[@cit17]^ ^*b*^ Molar ratio of *E* isomer and *Z* isomer of **16** determined by GC analysis.](c5dt04506a-f5){#fig5}

![Plausible intermediates for (a) **18** and (b) **8**.](c5dt04506a-f6){#fig6}

###### Selected data for the CM of **14** and **15** [^*a*^](#tab1fna){ref-type="fn"}

  Entry                                     Cat.      Cat. load[^*b*^](#tab1fnb){ref-type="table-fn"}, mol%   Solvent      Time, min   **16**                                       **17**                                                                                    
  ----------------------------------------- --------- ------------------------------------------------------- ------------ ----------- -------------------------------------------- -------------------------------------------- -------------------------------------------- --------------------------------------------
  1[^*e*^](#tab1fne){ref-type="table-fn"}   **7**     2.5                                                     CH~2~Cl~2~   2           75                                           8.4                                          4.0                                          4.40
                                                                                                              30           72          10.1                                         5.0                                          5.9                                          
  2                                         **8a**    2.5                                                     CH~2~Cl~2~   30          34                                           3.3                                          0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}
                                                                                                              120          74          6.1                                          2.5                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   
  3                                         **8b**    2.5                                                     CH~2~Cl~2~   30          28                                           3.2                                          0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}
                                                                                                              120          73          5.7                                          2.8                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   
  4                                         **11a**   5.0                                                     CH~2~Cl~2~   30          6.2                                          2.2                                          0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}
                                                                                                              120          34          3.2                                          0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   
  5                                         **11b**   5.0                                                     CH~2~Cl~2~   30          0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}
                                                                                                              120          0.0         (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   0.0                                          (NA)[^*f*^](#tab1fnf){ref-type="table-fn"}   

^*a*^All reactions were carried out using 0.20 mmol of **14**, 0.40 mmol of **15** and 0.10 mmol of tridecane (internal standard for GC analysis) in 1.0 ml of solvent at 23 °C.

^*b*^Based on **14**.

^*c*^Conversion of **14** to the product determined by GC analysis.

^*d*^Molar ratio of *E* isomer and *Z* isomer of the product determined by GC analysis.

^*e*^ [@cit15].

^*f*^GC signal of the product was too small to quantify.

### Ring opening metathesis polymerization (ROMP)

Next, the ROMP of norbornene (**19**) was tested with the presented cationic catalysts ([Scheme 5](#sch5){ref-type="fig"}). In all cases, an immediate increase in the viscosity of the reaction solution was observed after stirring substrate **19** with the catalysts, indicating rapid polymerization. The conversion and *E*/*Z* ratio of the product poly-norbornene **20** are summarized in [Table 2](#tab2){ref-type="table"}. **8a--b** and **11a** were able to complete the reaction within 30 min at the presented condition. Even **11b**, which showed negligible activity in the RCM and CM reactions above, provided 70% yield of **20** after 30 min.
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###### Data for the ROMP of **19** [^*a*^](#tab2fna){ref-type="fn"}

  Entry   Cat.      Cat. load[^*b*^](#tab2fnb){ref-type="table-fn"}, mol%   Solvent      Time, min   **20**   
  ------- --------- ------------------------------------------------------- ------------ ----------- -------- ------
  1       **7**     1.0                                                     CD~2~Cl~2~   30          100      0.69
  2       **8a**    1.0                                                     CD~2~Cl~2~   30          100      0.70
  3       **8b**    1.0                                                     CD~2~Cl~2~   30          100      0.69
  4       **11a**   1.0                                                     CD~2~Cl~2~   30          100      0.68
  5       **11b**   1.0                                                     CD~2~Cl~2~   30          70       0.65

^*a*^All reactions were carried out using 0.20 mmol of **19** and 0.002 mmol of catalyst in 0.8 ml of solvent at 23 °C.

^*b*^Based on **19**.

^*c*^Conversion of **19** to **20** determined by ^1^H NMR analysis.

^*d*^Molar ratio of *E* isomer and *Z* isomer of **20** determined by ^1^H NMR analysis.

Experimental section
====================

General information
-------------------

### Atmosphere

All reactions were carried out in dry glassware under an argon atmosphere using standard Schlenk techniques or in a Vacuum Atmospheres Glovebox under a nitrogen atmosphere unless otherwise specified.

### Solvents

CD~2~Cl~2~ was dried over CaH~2~ and vacuum transferred to a dry Schlenk flask and subsequently degassed with argon. Ethyl vinyl ether and isopropyl alcohol were used as received. All the other solvents were purified by passage through solvent purification columns and further degassed with argon.^[@cit18]^

### Materials

\[H~2~IMes~2~\]RuCl~2~\[CH-*o*-(O^i^Pr)C~6~H~4~\] (**7**, H~2~I = imidazolidinylidene, Mes = mesityl) was obtained from Materia, Inc. \[H~2~I(Mes)~2~\]RuCl~2~(PPh~3~)(CHPh) (**9**) was synthesized according to the literature procedure.^[@cit14]^ Diethyldiallyl malonate (**12**), allylbenzene (**14**), *cis*-1,4-diacetoxy-2-butene (**15**) and tridecane were distilled over CaH~2~ and stored under nitrogen in Schlenk flasks. Norbornene (**19**) was purified by sublimation before use. All the other commercially available reagents were used as received without further purification.

### Instruments

^1^H, ^13^C and ^31^P NMR spectra were recorded on a Varian 500 MHz spectrometer or a Varian 300 MHz spectrometer. High-resolution mass spectra were provided by the California Institute of Technology Mass Spectrometry Facility using JEOL JMS-600H High Resolution Mass Spectrometer. X-ray crystallographic data were collected by the California Institute of Technology Beckman Institute X-ray Crystallography Facility using Bruker KAPPA APEXII X-ray diffractometer. Gas chromatography data were obtained using Agilent 6850 FID gas chromatograph equipped with a DB-Wax polyethylene glycol capillary column (Agilent).

Catalyst syntheses
------------------

### General procedure for the synthesis of {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}X (**8**)

In a glove box, **7**, the corresponding silver salt, triphenylphosphine and dichloromethane were added into a 20 ml screw-cap vial equipped with a magnetic stir bar. The reaction mixture was stirred at room temperature for 2 h under dark. The resulting slurry was filtered and the filtrate was evaporated. The crude product was recrystallized from CH~2~Cl~2~--pentane or THF at --20 °C.

### {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}BF~4~ (**8a**)

Starting from **7** (300 mg, 479 μmol), AgBF~4~ (103 mg, 527 μmol) and triphenylphosphine (151 mg 575 μmol) in 10 ml of CH~2~Cl~2~, **8a** was obtained as a red-orange crystalline solid (397 mg, 422 μmol, 88.1% yield based on **7**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 15.16 (d, *J* = 7.0 Hz, 1H), 8.0--6.3 (br, 15H), 7.55--7.51 (m, 1H), 7.24 (d, *J* = 8.5 Hz, 1H), 7.17 (br s, 1H), 6.95--6.92 (m, 1H), 6.69--6.67 (m, 1H), 6.53 (br s, 1H), 6.42 (br s, 1H), 6.04 (br s, 1H), 5.74 (sep, *J* = 6.7 Hz, 1H), 4.20 (br s, 1H), 4.05 (br s, 1H), 3.97 (br s, 1H), 3.63 (br s, 1H), 2.93 (br s, 3H), 2.35 (br s, 3H), 2.07 (br s, 3H), 1.97 (br s, 3H), 1.88--1.86 (br m, 6H), 1.59 (d, *J* = 6.7 Hz, 3H), 1.30 (br s, 3H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 289.4 (d), 208.9 (d), 154.1, 142.0, 141--140 (br m), 137--136 (br m), 136.0 (br s), 135.1 (br s), 135--134 (br m), 133--132 (br m), 132.7, 132--131 (br m), 130.0 (br s), 130--128 (br m), 126.9, 122.9, 118.0, 81.8, 23.4, 22.8, 22--21 (br, m), 20.7 (br s), 20--19 (br m), 17.7 (br s). ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 53.6. HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}^+^: 853.2628, Found: 853.2617.

### {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}OTf (**8b**)

Starting from **7** (300 mg, 479 μmol), AgOTf (135 mg, 527 μmol) and triphenylphosphine (151 mg 575 μmol) in 10 ml of CH~2~Cl~2~, **8b** was obtained as a red-orange crystalline solid (277 mg, 276 μmol, 57.6% yield based on **7**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 15.15 (d, *J* = 7.3 Hz, 1H), 8.0--6.3 (br, 15H), 7.54--7.51 (m, 1H), 7.22 (d, *J* = 8.2 Hz, 1H), 7.17 (br s, 1H), 6.94--6.91 (m, 1H), 6.68--6.66 (m, 1H), 6.53 (br s, 1H), 6.42 (br s, 1H), 6.04 (br s, 1H), 5.74 (sep, *J* = 6.7 Hz, 1H), 4.19 (br s, 1H), 4.04 (br s, 1H), 3.96 (br s, 1H), 3.64 (br s, 1H), 2.92 (br s, 3H), 2.35 (br s, 3H), 2.07 (br s, 3H), 1.97 (br s, 3H), 1.87--1.86 (br m, 6H), 1.58 (d, *J* = 6.7 Hz, 3H), 1.30 (br s, 3H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 209.1 (d), 154.2, 154.2, 142.0, 141--140 (br m), 137--136 (br m), 136.0 (br s), 135.1 (br s), 135--134 (br m), 133--132 (br m), 132.7, 132--131 (br m), 130.1 (br s), 130--128 (br m), 127.0, 122.9, 118.0, 81.8, 23.5, 22.8, 22--21 (br, m), 20.7 (br s), 20--19 (br m), 17.8 (br s). ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 53.5. HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}^+^: 853.2628, Found: 853.2666.

### {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}PF~6~ (**8c**)

Starting from **7** (300 mg, 479 μmol), AgPF~6~ (133 mg, 527 μmol) and triphenylphosphine (151 mg 575 μmol) in 10 ml of CH~2~Cl~2~, **8c** was obtained as a red-orange crystalline solid (406 mg, 406 μmol, 84.7% yield based on **7**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 15.16 (d, *J* = 7.3 Hz, 1H), 8.0--6.3 (br, 15H), 7.55--7.51 (m, 1H), 7.23 (d, *J* = 8.5 Hz, 1H), 7.18 (br s, 1H), 6.95--6.92 (m, 1H), 6.69--6.68 (m, 1H), 6.53 (br s, 1H), 6.42 (br s, 1H), 6.05 (br s, 1H), 5.74 (sep, *J* = 6.7 Hz, 1H), 4.18 (br s, 1H), 4.03 (br s, 1H), 3.96 (br s, 1H), 3.63 (br s, 1H), 2.93 (br s, 3H), 2.35 (br s, 3H), 2.07 (br s, 3H), 1.98 (br s, 3H), 1.88--1.86 (br m, 6H), 1.59 (d, *J* = 6.7 Hz, 3H), 1.30 (br s, 3H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 289.5 (d), 209.0 (d), 154.2, 154.2, 142.0, 141--140 (br m), 137--136 (br m), 136.0 (br s), 135.2 (br s), 135--134 (br m), 133--132 (br m), 132.7, 132--131 (br m), 130.0 (br s), 130--128 (br m), 127.0, 122.9, 118.0, 81.8, 23.5, 23.4, 22.8, 22--21 (br, m), 20.7 (br s), 20--19 (br m), 17.7 (br s). ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 53.5. HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}^+^: 853.2628, Found: 853.2647.

### {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}SbF~6~ (**8d**)

Starting from **7** (300 mg, 479 μmol), AgSbF~6~ (181 mg, 527 μmol) and triphenylphosphine (151 mg 575 μmol) in 10 ml of CH~2~Cl~2~, **8d** was obtained as a red-orange crystalline solid (490 mg, 450 μmol, 93.9% yield based on **7**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 15.17 (d, *J* = 7.3 Hz, 1H), 8.0--6.3 (br, 15H), 7.55--7.51 (m, 1H), 7.22 (d, *J* = 8.5 Hz, 1H), 7.18 (br s, 1H), 6.95--6.92 (m, 1H), 6.69--6.67 (m, 1H), 6.54 (br s, 1H), 6.42 (br s, 1H), 6.05 (br s, 1H), 5.74 (sep, *J* = 6.7 Hz, 1H), 4.16 (br s, 1H), 4.02 (br s, 1H), 3.96 (br s, 1H), 3.62 (br s, 1H), 2.92 (br s, 3H), 2.35 (br s, 3H), 2.07 (br s, 3H), 1.98 (br s, 3H), 1.87--1.86 (br m, 6H), 1.59 (d, *J* = 6.7 Hz, 3H), 1.31 (br s, 3H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 289.5 (d), 209.1 (d), 154.2, 154.2, 142.0, 141--140 (br m), 137--136 (br m), 136.0 (br s), 135.2 (br s), 135--134 (br m), 133--132 (br m), 132.7, 132--131 (br m), 130.1 (br s), 130--128 (br m), 127.0, 122.9, 118.0, 81.8, 23.5, 23.4, 22.8, 22--21 (br, m), 20.7 (br s), 20--19 (br m), 17.7 (br s). ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 53.5. HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl(PPh~3~)\[CH-*o*-(O^i^Pr)C~6~H~4~\]}^+^: 853.2628, Found: 853.2643.

### General procedure for the synthesis of {\[H~2~IMes~2~\]RuCl\[Ph~2~P(CH~2~)~*n*~PPh~2~\](CHPh)}(OTf) (**11**)

In a glove box, **9** and CH~2~Cl~2~ were added into a 20 ml screw-cap vial equipped with a magnetic stir bar. With stirring, trimethylsilyl trifluoromethanesulfonate was added slowly. After stirring at room temperature for 1 h, the corresponding diposphine was added. Then the reaction solution was stirred at room temperature for 2 h, and evaporated. The crude product was dissolved in a small amount of CH~2~Cl~2~. The solution was added dropwise with vigorous stirring into a large amount of pentane (for **11a**) or Et~2~O (for **11b**). The appeared precipitate was corrected on a filter, washed with appropriate solvent, and dried under reduced pressure.

### {\[H~2~IMes~2~\]RuCl\[Ph~2~P(CH~2~)~2~PPh~2~\](CHPh)}(OTf) (**11a**)

Starting from **9** (100 mg, 120 μmol), TMS(OTf) (24.0 μl, 29.5 mg, 133 μmol) and DPPE (57.5 mg 144 μmol) in 5.0 ml of CH~2~Cl~2~, **11a** was obtained as a yellow-brown solid (76.7 mg, 71.0 μmol, 53.4% yield based on **9**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 16.23 (dd, *J* = 26.9 Hz, *J* = 1.2 Hz, 1H), 7.87--7.76 (m, 5H), 7.69--7.56 (m, 1H), 7.53--7.19 (m, 12H), 7.04 (s, 1H), 6.92--6.88 (m, 2H), 6.85--6.76 (m, 2H), 6.62--6.59 (m, 4H), 6.43 (s, 1H), 5.60 (s, 1H), 4.06--4.00 (m, 1H), 3.93--3.87 (m, 1H), 3.81--3.70 (m, 2H), 2.76 (s, 3H), 2.42 (s, 3H), 2.28 (s, 3H), 2.19--2.13 (br m, 1H), 2.10--2.03 (br m, 1H), 1.94 (s, 3H), 1.82 (s, 3H), 1.40--1.34 (br m, 1H), 1.17 (s, 3H), 0.68--0.64 (br m, 1H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 213.1 (dd), 149.0, 141.5, 140.0, 139.6, 139.4, 138.3, 137.7, 136.8, 135.9, 135.6, 135.3, 135.2, 135.0, 133.9, 133.9, 133.7, 133.3, 132.5--132.4 (m), 132.0, 131.9, 131.9, 131.3--131.2 (m), 130.9, 130.8--130.8 (m), 130.6--130.6 (m), 130.5, 130.4, 130.2--130.2 (m), 129.9, 129.0, 128.9, 128.9, 128.9, 128.5, 128.5, 128.4, 128.2, 41.4--41.0 (m), 21.8--21.4 (m), 21.0--20.9 (m), 20.6--20.5 (m), 18.9--18.9 (m), 18.0--18.0 (m), 15.9. ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 53.4 (d), 52.4 (d). HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl\[Ph~2~P(CH~2~)~2~PPh~2~\](CHPh)}^+^: 931.2651, Found: 931.2671.

### {\[H~2~IMes~2~\]RuCl\[Ph~2~P(CH~2~)~3~PPh~2~\](CHPh)}(OTf) (**11b**)

Starting from **9** (100 mg, 120 μmol), TMS(OTf) (24.0 μl, 29.5 mg, 133 μmol) and DPPP (59.6 mg 144 μmol) in 5.0 ml of CH~2~Cl~2~, **11b** was obtained as a yellow solid (78.7 mg, 71.9 μmol, 59.7% yield based on **9**). ^1^H NMR (500 MHz, CD~2~Cl~2~): *δ*/ppm 16.83 (dd, *J* = 26.5 Hz, *J* = 1.2 Hz, 1H), 7.68--7.60 (m, 7H), 7.50--7.44 (m, 3H), 7.39--7.36 (m, 2H), 7.32--7.28 (m, 3H), 7.17--7.14 (m, 3H), 7.11--7.08 (br m, 2H), 6.87--6.84 (m, 2H), 6.67--6.64 (br m, 2H), 6.62 (s, 1H), 6.48 (s, 1H), 6.41--6.37 (br m, 2H), 5.73 (s, 1H), 4.02--3.95 (m, 1H), 3.84--3.78 (m, 1H), 3.71--3.66 (m, 2H), 2.83 (s, 3H), 2.42 (s, 3H), 2.31--2.19 (br m, 3H), 2.12 (s, 3H), 1.95 (s, 3H), s1.89 (s, 3H), 1.78--1.73 (br m, 1H), 1.57--1.50 (br m, 1H), 1.15 (s, 3H), 0.93--0.80 (br m, 1H). ^13^C{^1^H} NMR (125.7 MHz, CD~2~Cl~2~): *δ*/ppm 211.0 (dd), 150.2, 150.2, 141.5, 140.1, 139.4, 139.0, 138.3, 138.1, 137.5--137.5 (m), 137.2--137.2 (m), 137.1, 136.0, 135.9, 135.6, 134.7, 134.7, 133.7, 133.5, 133.4, 133.2, 133.1, 131.7--131.7 (m), 131.6--131.6 (m), 131.3, 131.2, 131.0, 130.6, 130.6, 130.2, 130.1, 130.0, 129.8, 129.8, 129.4, 129.0, 128.7. 128.5, 128.4, 127.6, 127.5, 36.5--36.2 (m), 23.4, 23.2, 21.5--21.0 (m), 19.4--19.4 (m), 18.3, 18.0--18.0 (m), 16.8. ^31^P{^1^H} NMR (121.4 MHz, CD~2~Cl~2~): *δ*/ppm 18.9 (d), 3.5 (d). HRMS (FAB+): Calculated for {\[H~2~IMes~2~\]RuCl\[Ph~2~P(CH~2~)~3~PPh~2~\](CHPh)}^+^: 945.2808, Found: 945.2801.

Crystal structure determination of **8c**
-----------------------------------------

Single crystals of **8c** were recrystallised by diffusion of pentane into a saturated CH~2~Cl~2~ solution of **8c**; a suitable crystal was mounted on a hand-crafted glass fiber with Paratone oil (Exxon) and transferred to the 100 K cold gas stream of an OxfordCryosystems 700 Series Cryostream Cooler on the Bruker KAPPA APEXII 02B diffractometer.

Crystal data. C~52~H~59~Cl~7~F~6~N~2~OP~2~Ru, *M* = 1253.17, monoclinic, *a* = 10.1739(4), *b* = 23.3587(10), *c* = 23.0472(9) Å, *U* = 5463.3(4) Å^3^, *T* = 100 K, space group *P*2~1~/*n* (no. 14), *Z* = 4, 160 797 reflections measured, 21 852 unique (*R* ~int~ = 0.056), which were used in all calculations. Refinement of *F* ^2^ against all reflections (except the omitted (0 1 1)) with the weights w = 1/*σ* ^2^(*F* ~o~ ^2^). All non-hydrogen atoms were refined anisotropically. The cation and solvent hydrogen atoms were treated differently. All hydrogen atoms in the cation were freely refined with four parameters, three positional and one isotropic displacement. The six hydrogen atoms on the three dichloromethane molecules were included into the model at geometrically calculated positions and refined using a riding model. The isotropic displacement parameters of these hydrogen atoms were fixed to 1.2 times the *U* ~eq~ value of the carbon atoms to which they are bonded. The final w*R*(*F* ^2^) was 0.059 (all data).

Metathesis assays
-----------------

### Representative procedure for RCM of diethyldiallyl malonate (**12**)^[@cit15]^

In a glove box, a 1.0 ml volumetric flask was charged with **8a** (7.5 mg, 8.0 μmol) and CD~2~Cl~2~ was added to prepare 1.0 ml of stock solution (0.008 M). CD~2~Cl~2~ (700 μl) and the stock solution (100 μl, 0.80 μmol) were added into an NMR tube with a screw-cap septum top. The sample was equilibrated at 30 °C in the NMR probe before **12** (19.3 μl, 19.2 mg, 80 μmol) was added *via* syringe. Data points were collected over an appropriate period of time using the Varian array function. The conversion of **12** to **13** was determined by comparing the ratio of the integrals of the methylene protons in the starting material with those in the product in the ^1^H NMR spectra.

### Representative procedure for CM of allylbenzene (**14**) and *cis*-1,4-diacetoxy-2-butene (**15**)^[@cit15]^

#### Preparation of a substrate mixture

In a glove box, tridecane (92.0 μl, 69.6 mg, 377 μmol), **14** (100 μl, 89.2 mg, 755 μmol) and **15** (240 μl, 259 mg, 1.51 mmol) were combined in a 5 ml vial with a screw-cap septum top and a magnetic stir bar; this mixture was allowed to stir for 5 min.

#### Preparation of reaction solution and CM of **14** and **15**

In a glove box, a 5 ml vial with a screw-cap septum top and a magnetic stir bar was charged with **8a** (4.7 mg, 5.0 μmol) and CH~2~Cl~2~ (1.0 ml). The catalyst solution was removed from the glove box and then stirred at 23 °C under argon. To the catalyst solution, the substrate mixture (115 μl; tridecane: 24.5 μl, 18.5 mg, 100 μmol; **14**: 26.6 μl, 23.7 mg, 201 μmol; **15**: 63.9 μl, 69.0 mg, 401 μmol) was added *via* syringe. The reaction solution was allowed to stir at 23 °C and reaction aliquots (*ca*. 40 μl) were taken at the specific time points.

#### GC analysis

Samples for GC analysis were obtained by adding the reaction aliquot to 400 μl of a 3 M solution of ethyl vinyl ether in isopropyl alcohol. The sample was shaken and allowed to stand for 10 min. 100 μl of 1 M slurry of tris(hydroxymethyl)phosphine in isopropyl alcohol was added.^[@cit19]^ The sample was heated at 50 °C for 30 min, cooled to room temperature, passed through a pad of silica gel using CH~2~Cl~2~ as eluent and then analyzed by GC. GC response factor and retention time for each substrate were summarized in Table S6.[†](#fn1){ref-type="fn"} The amounts of the substrates in each sample were determined by previously reported method using response factors.^[@cit15]^

### Representative procedure for ROMP of norbornene (**19**)

A 2 ml volumetric flask was charged with **19** (125 mg, 1.33 mmol), and CD~2~Cl~2~ was added to prepare 2.0 ml of stock solution (0.665 M). In a glove box, **8a** (1.9 mg, 2.0 μmol) and CD~2~Cl~2~ (500 μl) were added into an NMR tube with a screw-cap septum top. The stock solution (300 μl; **19**: 18.8 mg, 200 μmol) was added *via* syringe and the sample was vigorously shaken for 30 seconds. Then the sample was allowed to stand for 30 min at 23 °C and analyzed by ^1^H NMR. The conversion of **19** to **20** was determined by comparing the ratio of the integrals of the olefinic protons in the starting material with those in the product in the ^1^H NMR spectrum.

Conclusion
==========

While aiming to discover a convenient methodology for the preparation of cationic ruthenium alkylidene catalysts, simple ligand exchange using silver([i]{.smallcaps}) salt of non-coordinating or weakly coordinating anion was investigated. When NHC-substituted catalyst **7** was reacted with a variety of silver([i]{.smallcaps}) salt in the presence of PPh~3~, cationic catalysts bearing a single PPh~3~ ligand **8a--d** were afforded selectively in good yield. Catalysts **8a--d** were shown to exhibit moderate activity in the standard metathesis reactions. In contrast to reported neutral catalysts bearing a single bulky ligand, the stereoselectivities of **8a--d** were very similar to that of dichloride substituted catalyst **7**. Additionally, diphosphines DPPE or DPPP were reacted with complex **9**, causing formation of cationic diphosphine-chelated catalysts **11a--b**. **11a--b** exhibited poor activity in the standard RCM and CM compared to **8a--d**, most likely due to slow initiation derived from the high energy barrier of dechelation of the diphosphine ligand. Modification of the charge of ruthenium alkylidene catalyst is a promising avenue of investigation in improving catalyst efficiency and expanding their applications. The simple methods presented in this report will enable easy access to similar cationic catalysts and facilitate further investigations.

We thank Dr M. B. Herbert for helpful discussions and suggestions for this work, Materia, Inc. for the generous donation of catalysts and Dr M. W. Day and Mr L. M. Henling for X-ray crystallography. The Bruker KAPPA APEXII X-ray diffractometer was purchased *via* an NSF CRIF:MU award to the California Institute of Technology, CHE-0639094. This work was financially supported by NIH (NIH 5R01GM031332), NSF (CHE-0410425 and CHE-0809418) and Mitsui Chemicals, Inc.

[^1]: †Electronic supplementary information (ESI) available: NMR spectra and metathesis data. CCDC [784488](784488). For ESI and crystallographic data in CIF or other electronic format see DOI: [10.1039/c5dt04506a](10.1039/c5dt04506a) Click here for additional data file. Click here for additional data file.
